ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

Post-LOE

acetaminophen; caffeine; dihydrocodeine bitartrate

Passkey Therapeutics

ANDAORALTABLET

Approved

Sep 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE (acetaminophen; caffeine; dihydrocodeine bitartrate) by Passkey Therapeutics is clinical pharmacology: acetaminophen, caffeine, and dihydrocodeine bitartrate tablets contain dihydrocodeine which is a semisynthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 2006.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets contain dihydrocodeine which is a semisynthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous…

Indications (2)

minor aches pains due to: headache sore throat flu toothache the common cold temporarily reduces fever

Worked on ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.